Clinical Trial Update: Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating darolutamide plus androgen deprivation therapy as neoadjuvant treatment for high-risk prostate cancer; the study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: Xijing Hospital | Conditions: Prostate Cancer | Phase 2 | Status: RECRUITING